Urteste S.A. is expanding development of innovative diagnostic projects, including one for early pancreatic cancer detection.

From GlobeNewswire: 2024-09-26 10:29:00

Urteste S.A., a biotechnology company based in Gdańsk, Poland, is expanding its innovative diagnostic projects. Their flagship project, PANURI, is a diagnostic test for pancreatic cancer that allows for early detection through urine samples. The company’s technology has shown high sensitivity (95.6%) and specificity (95.5%) in a proof-of-concept study of 322 participants. Urteste has also received a $3 million grant to develop a breast cancer diagnostic test called NASTRO. They are currently focused on developing a pipeline of 12 prototype diagnostic tests for various cancers, aiming to save lives through early cancer detection.



Read more at GlobeNewswire: Urteste Expands Development of Innovative Diagnostic